Figure 1
Figure 1. Morphologic change after IFN therapy in a patient with primary myelofibrosis. (A-D) Before treatment (2002). (A) The area of myelofibrosis (left), with preserved residual foci of hematopoiesis, and abnormal megakaryocyte morphology (right). (B) Abnormal megakaryocyte morphology. (C) 2+ reticulin fibrosis. (D) Collagen fibrosis. (E-H) After treatment (2009). (E) Improved bone marrow architecture, hematopoiesis, and megakaryocyte morphology. (F) Improved megakaryocyte morphology and increased normoblastic erythropoiesis. (G) Minimal reticulin fibrosis. (H) Absent collagen fibrosis.

Morphologic change after IFN therapy in a patient with primary myelofibrosis. (A-D) Before treatment (2002). (A) The area of myelofibrosis (left), with preserved residual foci of hematopoiesis, and abnormal megakaryocyte morphology (right). (B) Abnormal megakaryocyte morphology. (C) 2+ reticulin fibrosis. (D) Collagen fibrosis. (E-H) After treatment (2009). (E) Improved bone marrow architecture, hematopoiesis, and megakaryocyte morphology. (F) Improved megakaryocyte morphology and increased normoblastic erythropoiesis. (G) Minimal reticulin fibrosis. (H) Absent collagen fibrosis.

Close Modal

or Create an Account

Close Modal
Close Modal